Piedmont Investment Advisors Inc. grew its holdings in shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by 1.9% in the first quarter, HoldingsChannel.com reports. The firm owned 16,469 shares of the biopharmaceutical company’s stock after buying an additional 310 shares during the period. Piedmont Investment Advisors Inc.’s holdings in Alexion Pharmaceuticals were worth $2,226,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other large investors have also modified their holdings of ALXN. FMR LLC boosted its position in Alexion Pharmaceuticals by 25.1% during the fourth quarter. FMR LLC now owns 26,398,265 shares of the biopharmaceutical company’s stock worth $2,570,135,000 after purchasing an additional 5,301,272 shares during the period. Norges Bank bought a new position in shares of Alexion Pharmaceuticals in the fourth quarter valued at approximately $388,934,000. Janus Henderson Group PLC boosted its position in shares of Alexion Pharmaceuticals by 29.7% in the first quarter. Janus Henderson Group PLC now owns 1,325,355 shares of the biopharmaceutical company’s stock valued at $179,161,000 after acquiring an additional 303,359 shares during the period. Swedbank boosted its position in shares of Alexion Pharmaceuticals by 46.6% in the fourth quarter. Swedbank now owns 861,345 shares of the biopharmaceutical company’s stock valued at $83,731,000 after acquiring an additional 273,800 shares during the period. Finally, Investec Asset Management LTD boosted its position in shares of Alexion Pharmaceuticals by 16.7% in the first quarter. Investec Asset Management LTD now owns 1,673,504 shares of the biopharmaceutical company’s stock valued at $226,224,000 after acquiring an additional 240,014 shares during the period. Hedge funds and other institutional investors own 97.89% of the company’s stock.
A number of research firms have recently commented on ALXN. Zacks Investment Research lowered shares of Alexion Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday. Citigroup cut their price objective on shares of Alexion Pharmaceuticals from $180.00 to $165.00 and set a “buy” rating for the company in a research report on Thursday. Goldman Sachs Group restated a “neutral” rating and issued a $142.00 price objective on shares of Alexion Pharmaceuticals in a research report on Thursday. Wedbush began coverage on shares of Alexion Pharmaceuticals in a research report on Wednesday. They issued an “outperform” rating and a $173.00 price objective for the company. Finally, TheStreet upgraded shares of Alexion Pharmaceuticals from a “c” rating to a “b” rating in a research report on Thursday, April 25th. Seven research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. Alexion Pharmaceuticals has an average rating of “Buy” and a consensus target price of $161.06.
Shares of ALXN opened at $127.15 on Friday. The company has a market capitalization of $28.51 billion, a P/E ratio of 17.93, a P/E/G ratio of 1.01 and a beta of 1.53. The company has a current ratio of 3.87, a quick ratio of 3.36 and a debt-to-equity ratio of 0.25. Alexion Pharmaceuticals, Inc. has a 1-year low of $92.56 and a 1-year high of $141.86.
Alexion Pharmaceuticals (NASDAQ:ALXN) last announced its earnings results on Thursday, April 25th. The biopharmaceutical company reported $2.39 earnings per share for the quarter, beating analysts’ consensus estimates of $1.99 by $0.40. The business had revenue of $1.14 billion for the quarter, compared to the consensus estimate of $1.13 billion. Alexion Pharmaceuticals had a net margin of 9.59% and a return on equity of 19.53%. Alexion Pharmaceuticals’s quarterly revenue was up 22.5% on a year-over-year basis. During the same period last year, the firm posted $1.68 earnings per share. On average, analysts anticipate that Alexion Pharmaceuticals, Inc. will post 8.6 EPS for the current fiscal year.
TRADEMARK VIOLATION WARNING: This piece of content was first published by Stock Observer and is owned by of Stock Observer. If you are viewing this piece of content on another site, it was stolen and reposted in violation of US and international copyright law. The original version of this piece of content can be viewed at https://www.thestockobserver.com/2019/05/25/piedmont-investment-advisors-inc-raises-holdings-in-alexion-pharmaceuticals-inc-alxn.html.
About Alexion Pharmaceuticals
Alexion Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and Soliris (eculizumab), a monoclonal antibody for the treatment of PNH, atypical hemolytic uremic syndrome (aHUS), and generalized myasthenia gravis.
Recommended Story: What is total return in investing?
Want to see what other hedge funds are holding ALXN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN).
Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.